Role of Robotic Surgery in the management of benign hepatobiliary diseases
EAES Academy. kakiashvili e. 07/05/22; 363131; P176
CLICK HERE TO LOGIN
REGULAR CONTENT
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Background:
recently robotic surgery has emerged as one of the most promising surgical advances. Despite its worldwide acceptance in many different surgical specialties, the use of robotic assistance in the field of hepatobiliary (HBP) surgery remains relatively unexplored.
Our study presents single institution's initial experience of robotic assisted surgery for treatment of benign hepatobiliary pathologies.
Methods:
A retrospective analysis of a prospectively maintained database on clinical outcomes was performed for 32 consecutive patients that underwent robotic assisted surgery for benign HBP disease at Rambam Medical Center during 2013-2016.
Results:
There were 32 robotic assisted surgical procedures performed for benign HBP pathologies during the study period. There were 4 anatomical robotic liver resections for symptomatic hemangiomas , 9 cases of giant liver cyst, 5 robotic assisted surgery for type I choledochal cyst, 3 case of benign (iatrogenic) common bile duct (CBD) stricture, 5 cases of robotic (CBD) exploration due to large intra choledochal stones and 6 cases of cholecystectomy for cholelithiasis. The median postoperative hospital stays for all procedures were 3.5 days (range 1–6 days). General morbidity (minor) was 2%. There was no mortality in our series.
Conclusion:
Robotic surgery is feasible and can be safely performed in patients with different benign HBP pathologies. Further evaluation with clinical trials is required to validate it's real benefits.
recently robotic surgery has emerged as one of the most promising surgical advances. Despite its worldwide acceptance in many different surgical specialties, the use of robotic assistance in the field of hepatobiliary (HBP) surgery remains relatively unexplored.
Our study presents single institution's initial experience of robotic assisted surgery for treatment of benign hepatobiliary pathologies.
Methods:
A retrospective analysis of a prospectively maintained database on clinical outcomes was performed for 32 consecutive patients that underwent robotic assisted surgery for benign HBP disease at Rambam Medical Center during 2013-2016.
Results:
There were 32 robotic assisted surgical procedures performed for benign HBP pathologies during the study period. There were 4 anatomical robotic liver resections for symptomatic hemangiomas , 9 cases of giant liver cyst, 5 robotic assisted surgery for type I choledochal cyst, 3 case of benign (iatrogenic) common bile duct (CBD) stricture, 5 cases of robotic (CBD) exploration due to large intra choledochal stones and 6 cases of cholecystectomy for cholelithiasis. The median postoperative hospital stays for all procedures were 3.5 days (range 1–6 days). General morbidity (minor) was 2%. There was no mortality in our series.
Conclusion:
Robotic surgery is feasible and can be safely performed in patients with different benign HBP pathologies. Further evaluation with clinical trials is required to validate it's real benefits.
Background:
recently robotic surgery has emerged as one of the most promising surgical advances. Despite its worldwide acceptance in many different surgical specialties, the use of robotic assistance in the field of hepatobiliary (HBP) surgery remains relatively unexplored.
Our study presents single institution's initial experience of robotic assisted surgery for treatment of benign hepatobiliary pathologies.
Methods:
A retrospective analysis of a prospectively maintained database on clinical outcomes was performed for 32 consecutive patients that underwent robotic assisted surgery for benign HBP disease at Rambam Medical Center during 2013-2016.
Results:
There were 32 robotic assisted surgical procedures performed for benign HBP pathologies during the study period. There were 4 anatomical robotic liver resections for symptomatic hemangiomas , 9 cases of giant liver cyst, 5 robotic assisted surgery for type I choledochal cyst, 3 case of benign (iatrogenic) common bile duct (CBD) stricture, 5 cases of robotic (CBD) exploration due to large intra choledochal stones and 6 cases of cholecystectomy for cholelithiasis. The median postoperative hospital stays for all procedures were 3.5 days (range 1–6 days). General morbidity (minor) was 2%. There was no mortality in our series.
Conclusion:
Robotic surgery is feasible and can be safely performed in patients with different benign HBP pathologies. Further evaluation with clinical trials is required to validate it's real benefits.
recently robotic surgery has emerged as one of the most promising surgical advances. Despite its worldwide acceptance in many different surgical specialties, the use of robotic assistance in the field of hepatobiliary (HBP) surgery remains relatively unexplored.
Our study presents single institution's initial experience of robotic assisted surgery for treatment of benign hepatobiliary pathologies.
Methods:
A retrospective analysis of a prospectively maintained database on clinical outcomes was performed for 32 consecutive patients that underwent robotic assisted surgery for benign HBP disease at Rambam Medical Center during 2013-2016.
Results:
There were 32 robotic assisted surgical procedures performed for benign HBP pathologies during the study period. There were 4 anatomical robotic liver resections for symptomatic hemangiomas , 9 cases of giant liver cyst, 5 robotic assisted surgery for type I choledochal cyst, 3 case of benign (iatrogenic) common bile duct (CBD) stricture, 5 cases of robotic (CBD) exploration due to large intra choledochal stones and 6 cases of cholecystectomy for cholelithiasis. The median postoperative hospital stays for all procedures were 3.5 days (range 1–6 days). General morbidity (minor) was 2%. There was no mortality in our series.
Conclusion:
Robotic surgery is feasible and can be safely performed in patients with different benign HBP pathologies. Further evaluation with clinical trials is required to validate it's real benefits.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}